The FDA approved LuPSMA (Pluvicto) + androgen receptor pathway inhibitor therapy for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer. Approval is based on the PSMAddition trial. Congrats to everyone whose hard work led to this new option for patients!👏
